Chairs: R. Eeeles, UK - H. Vasen, NL - J. Benitez, ES
The 6th Familial Cancer Conference hosted once again at the Spanish National Cancer Research Centre (CNIO) aims to present the advances in this field from a multidisciplinary point of view. As you know, familial cancer has become an important challenge for oncologists, geneticists, molecular biologists and other professionals, due to its implications not only at the individual but also at the familial and social level. This type of cancers affect several members of a single family, being the identification of high risk families, the knowledge of the genes responsible for specific diseases and their biological functions, the clinical follow up of mutation carriers, the development of new treatments and the discovery of tailored drugs, some of the different challenges involved. In most of countries, the number of professionals working in familial cancer has increased in the last years, demonstrating the interest that has woke up in our society. The Conference wants not only to cover and update numerous topics related to these genetic diseases but also to be a forum of discussion and meeting for professionals, either experienced clinicians and scientists or young people that are starting to work, or just interested in this exiting world.
Thank you all for coming to Madrid and we hope you enjoy a pleasant and successful Conference.
Javier Benitez, Hans Vasen, Rosalind Eeles
• To update recent advances in familial cancer
• To better define the genetic profile of these cancers and the clinical management of families and patients.
• To depth in the new therapeutic strategies based in animal models
• To analyze the impact of the new technologies and their contribution to familial cancer risk
• General concepts in familial cancer; genetic variants and familial cancer; genetic counseling
• Common cancers: The family of breast cancer genes; selection criteria and clinical management; new treatments based in animal models and massive sequencing; colorectal cancer and prostate cancer; genetic and clinical management.
• Other hereditary syndromes: Familial pheocromocitoma; pancreatic cancer; PTEN-Hamartoma syndromes; familial renal carcinoma; familial melanoma; li Fraumeni syndrome; gastric carcinoid; Fanconi anemia
• New technologies applied to research and clinical diagnosis; the role of Consortia in massive sequencing; what to do with the incidental findings?
The 6th Familial
Scientific Events Office
Centro Nacional de Investigaciones Oncológicas (CNIO)
(Spanish National Cancer Research Centre)
Melchor Fernández Almagro 3
firstname.lastname@example.org - www.cnio.es
European School of Oncology
Via Turati, 29
20121 Milan - Italy
Tel: +39 02 8546 4523
Fax: +39 02 8546 4545
Centro Nacional de Investigaciones
Oncológicas (CNIO) - Auditorium
Melchor Fernández Almagro, 3
The official language of the conference will be English. No simultaneous translation will be provided.
CME ACCREDITATION AND CERTIFICATES OF ATTENDANCE
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). Information on the status of the applications can be obtained from the organising secretariat.
All participants will be issued with a certificate of attendance at the close of the conference in return of the completed evaluation questionnaire.
The badge is the only official evidence of registration and should be worn at all times during the conference. Loss of badge means loss of registration.
The organisers bear no responsibility for untoward events in connection with, before, during and after the conference. Participants are strongly advised to take out their own personal and travel insurance coverage.
15/05/2014: poster/abstract submission and registration deadline
15/05/2014: cancellation deadline
24/05/2014: replacement deadline
L. Aaltonen, University of Helsinki, FI
J. Benítez, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
G. Capellà, Instituto Catalán Oncología, Barcelona, ES
P. Devilee, Leiden University Medical Centre, NL
R. Eeles, The Royal Marsden Hospital, Sutton, UK
D. Eccles, Southampton University Hospital Trust, UK
T. Frebourg, Rouen University Hospital, FR
S. Hodgson, St. George's Hospital Medical School, London, UK
E. Maher, University of Birmingham, UK
F. Menko, VU University Medical Center, Amsterdam, NL
R. Milne, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
J.A. Newton-Bishop, University of Leeds, St James’ University Hospital, UK
A. Osorio, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
M. Pritchard, University of Liverpool, UK
M. Robledo, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
J. Surrallés, Universitat Autónoma de Barcelona, ES
M. Urioste, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
H. Vasen, Leiden University Medical Centre, Leiden, NL
A. Villanueva, Instituto Catalán Oncología, Barcelona, ES
J. Benítez, ES
Hereditary cancer syndromes. An overview
Low susceptibility alleles and familial cancer risk
|Genetic counseling in hereditary cancer|
S. Hodgson, UK
Picture, posters, coffee break
|COMMON CANCERS I|
Chair: F. Menko, NL
The landscape of breast cancer genes
|Selection criteria and clinical management|
D. Eccles, UK
|Personalized treatment strategies based in animal models|
A. Villanueva, ES
COMMON CANCERS II
(Epi) Genetics of colorectal cancer syndromes
|Guidelines for the management of Lynch syndromes|
H. Vasen, NL
|Familial prostate cancer. Genetics, clinical management and diagnostic biomarkers |
R. Eeles, UK
|Clinical session |
H. Vasen, NL- R. Eeles, UK
|OTHER HEREDITARY CANCER SYNDROMES I|
Chair: H. Vasen, NL
Familial pheochromocytoma. An example of genetic heterogeneity
The genetics and genomics of familial renal carcinoma
|Clinical and genetic characteristics of malignant melanoma|
J.A. Newton-Bishop, UK
|OTHER HEREDITARY CANCER SYNDROMES II|
Chair: P. Devilee, NL
Li Faumeni syndrome. Genetics and clinical surveillance
Gastric carcinoid. A rare neuro endocrine tumor
Fanconi anemia: at the crossroad between DNA repair and cancer predisposition pathways
NEW TECHNOLOGIES APPLIED TO FCS
|Research and clinical application of familial cancer exome sequencing|
J. Benítez, ES
|14:50||COMPLEXO: A consortium to decipher the genetic complexity of familial breast cancer|
P. Devilee, NL
|Incidental findings in WES. What to do with these data?|
L. Aaltonen, FI
POSTER/ABSTRACT SUBMISSION DEADLINE: 15 MAY 2014
You may apply and submit your abstract to the organising secretariat online at: www.cnio.es/meetings
INSTRUCTIONS FOR APPLICATION SUBMISSION
- Participants with new data relevant to the subject of the conference may submit one abstract to be considered for poster presentation. Only papers whose abstracts have been reviewed and approved by the conference coordinators will be presented.
- Abstracts should be written in English and the text should not exceed 3000 characters, title included.
- The title should appear in capital letters.
- For each author, type surname first, followed by first name and initials (presenting author in capital letters).
- List of affiliations after the author's list.
- Indicate 3-5 keywords at the end of the text.
- The full address with telephone, fax number and email of the corresponding author must be provided. The corresponding author will receive all the subsequent communication concerning this abstract. Please also indicate your approval for publication in case the abstracts are issued in a journal.
- Six abstracts will be selected for the oral presentation. We will notify it to the first author before May 15th.
- It is the responsibility of the presenting author to ascertain whether all authors are aware of the content of the abstract before submission.
The poster size must be 70 cm width and 120 cm height.
On both conference days after lunch break, 30 minutes have been reserved for poster discussion session. First authors are requested to stay on ground floor next to the poster during that period of time.